Dr. Sareena Singh, MD | Canton, OH ...

Dr. Sareena Singh

Claim this profile

Aultman Health Foundation

Studies Endometrial Adenocarcinoma
Studies Uterine Cancer
9 reported clinical trials
18 drugs studied

Area of expertise

1

Endometrial Adenocarcinoma

Sareena Singh has run 5 trials for Endometrial Adenocarcinoma. Some of their research focus areas include:

Stage I
Stage III
Stage IV
2

Uterine Cancer

Sareena Singh has run 5 trials for Uterine Cancer. Some of their research focus areas include:

Stage I
Stage III
Stage IV

Affiliated Hospitals

Image of trial facility.

Aultman Health Foundation

Image of trial facility.

Aultman Alliance Community Hospital

Clinical Trials Sareena Singh is currently running

Image of trial facility.

Selinexor Maintenance Therapy

for Endometrial Cancer

The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.

Recruiting

1 award

Phase 3

2 criteria

Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.

Recruiting

2 awards

Phase 3

More about Sareena Singh

Clinical Trial Related

7 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Sareena Singh has experience with

  • Pembrolizumab
  • Olaparib
  • Cediranib Maleate
  • Durvalumab
  • Carboplatin
  • Paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sareena Singh specialize in?

Is Sareena Singh currently recruiting for clinical trials?

Are there any treatments that Sareena Singh has studied deeply?

What is the best way to schedule an appointment with Sareena Singh?

What is the office address of Sareena Singh?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security